6-K 1 v467025_6k.htm FORM 6-K

 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

May 2017

 

Commission file number: 001-36288

 

Akari Therapeutics, Plc

(Translation of registrant's name into English)

 

75/76 Wimpole Street

London W1G 9RT

United Kingdom

Tel: (646) 448-8743

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x       Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

 

 

 

 

CONTENTS

 

 

 

On May 15, 2017, Akari Therapeutic, Plc (the “Company”) announced that it will hold its Annual General Meeting of Shareholders on June 28, 2017.  In connection with the meeting, the Company furnishes the following documents:

 

1.Notice and Proxy Statement to Shareholders dated May 15, 2017

 

2.Statutory Accounts for the year ended December 31, 2016

 

3.Form of Proxy Card

 

 

The information contained in this report (including the exhibit hereto) is hereby incorporated by reference into the Company’s Registration Statement on Form S-3, File No. 333-207443, Form S-8 (No. 333-198109 and 333-207444), Registration Statement on Form F-3 File No. 333-198107, and the Registration Statements on Post-Effective Amendments to Form F-1 on Form F-3 (333-185247, 333-187826 and 333-191880).

 

Exhibit No.

 

99.1 Notice of Annual General Meeting of Shareholders and Proxy Statement

 

99.2 Statutory Accounts for the year ended December 31, 2016  
   
99.3 Form of Proxy Card

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Akari Therapeutics, Plc  
  (Registrant)  
       
  By: /s/ Robert M. Shaw  
  Name:   Robert M. Shaw  
  General Counsel & Secretary  

       

Date: May 16, 2017